98,092 Shares in Elanco Animal Health Incorporated (NYSE:ELAN) Acquired by Centiva Capital LP

Centiva Capital LP acquired a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 98,092 shares of the company's stock, valued at approximately $1,188,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB bought a new stake in Elanco Animal Health in the third quarter worth $35,000. Jones Financial Companies Lllp grew its holdings in Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock valued at $51,000 after purchasing an additional 2,059 shares during the last quarter. SRS Capital Advisors Inc. grew its stake in Elanco Animal Health by 221.2% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock valued at $60,000 after buying an additional 3,411 shares during the last quarter. MRP Capital Investments LLC bought a new stake in Elanco Animal Health during the fourth quarter valued at about $61,000. Finally, Blue Trust Inc. grew its position in shares of Elanco Animal Health by 47.7% in the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock valued at $71,000 after purchasing an additional 1,894 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock traded up $0.23 during trading on Tuesday, reaching $13.05. The company's stock had a trading volume of 2,763,330 shares, compared to its average volume of 4,989,110. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The business's 50-day moving average price is $9.93 and its 200-day moving average price is $11.42. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $18.80. The firm has a market cap of $6.48 billion, a PE ratio of 32.63, a P/E/G ratio of 2.50 and a beta of 1.49.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, topping analysts' consensus estimates of $0.31 by $0.06. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The company's revenue was down 1.0% on a year-over-year basis. During the same quarter last year, the company earned $0.34 EPS. Equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ELAN shares. Piper Sandler cut their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, March 6th. Morgan Stanley cut their price objective on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, February 26th. UBS Group reduced their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Stifel Nicolaus lifted their target price on shares of Elanco Animal Health from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Finally, Barclays reduced their price objective on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $15.00.

Insider Buying and Selling at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius bought 10,000 shares of the business's stock in a transaction on Friday, March 7th. The shares were purchased at an average price of $10.90 per share, for a total transaction of $109,000.00. Following the completion of the transaction, the director now directly owns 101,459 shares of the company's stock, valued at approximately $1,105,903.10. This represents a 10.93% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.89% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.